YOLFTbeta
Ilyang Pharmaceutical Co.,Ltd

Ilyang Pharmaceutical Co.,Ltd

007575 · KO · Healthcare / Drug Manufacturers - Specialty & Generic

6,780.00KRW+140.00 (+2.11%)

Price History

Full chart

Market Stats

Previous Close6,640.00
Open6,730.00
Day Range6,710.00 – 6,780.00
52-Week Range6,350.00 – 15,260.00
Volume29
Market Cap319.63B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.24%
Beta0.38
50-Day Avg7,764.80
200-Day Avg10,123.15

About

Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, antifungal drugs, anti-inflammatory analgesic drugs, insecticides, and vaccines; and health drinks, daily food, supplements, health food, cosmetics, and beverages. In addition, the company offers pharmaceutical raw materials products, such as aluminum hydroxide gel, dried aluminum hydroxide gel, magnesium hydroxide, magnesium hydroxide gel, aluminum hydroxide-magnesium carbonate co-dried gel, magnesium trisilicate, hydrotalcite, almagate, aluminum phosphate, aluminum phosphate gel, aluminum magnesium metasilicate, aluminum magnesium silicate, aluminum magnesium silicopolydrate, magaldrate, magaldrate wet gel, dihydroxy aluminum sodium carbonate, magnesium carbonate, aluminum magnesium hydroxide, synthetic aluminum silicate, and other products. Ilyang Pharmaceutical Co.,Ltd also exports its products. The company was formerly known as Il-Yang Pharm. Ind. Co. and changed its name to Ilyang Pharmaceutical Co., Ltd. in May 1991. Ilyang Pharmaceutical Co.,Ltd was founded in 1946 and is headquartered in Yongin-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Dong-Yeon Kim
  • Employees660
  • Headquarters110, Hagal-ro, Yongin-si, South Korea, 17096, Korea
  • Websitehttps://home.ilyang.co.kr

Leadership

  • Mr. Dong-Yeon KimCEO, President & Director · b. 1950
  • Mr. Yoo-Suk JungSenior MD & Director · b. 1976
  • Mr. Kyu-Young ChoiMD & Director · b. 1958

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue211.80B239.26B261.61B269.81B300.04B324.57B343.33B371.35B383.81B266.67B268.68B272.42B
Growth (%)-+12.97%+9.34%+3.13%+11.20%+8.18%+5.78%+8.16%+3.36%-30.52%+0.75%+1.39%
Cost of Revenue118.92B130.29B138.18B133.63B145.74B145.80B161.62B166.94B167.78B150.18B157.39B156.07B
Gross Profit92.88B108.98B123.44B136.18B154.29B178.77B181.71B204.40B216.03B116.49B111.29B116.35B
Gross Margin43.85%45.55%47.18%50.47%51.43%55.08%52.93%55.04%56.29%43.68%41.42%42.71%
Operating Expense86.63B89.73B100.25B111.75B137.57B146.26B147.61B163.38B175.62B100.11B101.67B111.39B
Operating Income6.25B19.25B23.18B24.43B16.72B32.51B34.10B41.03B40.41B16.38B9.62B4.96B
Operating Margin2.95%8.04%8.86%9.06%5.57%10.02%9.93%11.05%10.53%6.14%3.58%1.82%
EBITDA---34.86B24.64B41.99B44.07B53.64B56.85B13.40B23.65B24.63B
EBITDA Margin---12.92%8.21%12.94%12.84%14.44%14.81%5.02%8.80%9.04%
Net Income-10.96B4.41B5.91B6.26B-4.89B9.98B10.88B14.38B19.24B-2.41B9.03B6.90B
Net Income Margin-5.18%1.84%2.26%2.32%-1.63%3.08%3.17%3.87%5.01%-0.90%3.36%2.53%
R&D8.36B14.39B10.11B12.39B12.84B15.85B19.72B20.20B25.96B23.75B24.74B26.10B
R&D as % of Total Revenue3.95%6.01%3.87%4.59%4.28%4.88%5.74%5.44%6.76%8.91%9.21%9.58%
Interest Expense00004.55B4.23B3.02B2.06B2.46B3.23B2.93B3.03B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.52%1.30%0.88%0.55%0.64%1.21%1.09%1.11%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets430.83B431.63B431.26B436.37B432.25B437.46B439.12B494.27B498.19B356.66B431.03B457.33B
Total Liabilities247.37B220.62B213.91B225.39B222.37B214.72B194.19B222.51B206.33B160.25B191.49B215.92B
Total Equity172.31B193.80B199.61B191.95B187.49B196.90B207.19B224.11B234.65B196.41B235.95B237.60B
Cash14.50B9.47B13.31B23.55B22.21B35.90B41.34B47.73B59.60B79.70M4.30B23.65B
Net Debt---130.81B121.75B92.23B61.40B53.35B25.02B71.71B102.91B102.56B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow18.63B40.27B26.98B30.03B22.12B36.19B57.48B67.02B29.94B14.62B5.61B12.04B
Investing Cash Flow-20.42B-31.97B-10.62B-12.99B-11.42B-1.22B-21.16B-21.34B7.59B---
Financing Cash Flow11.22B-9.61B-12.30B-5.82B-11.53B-21.65B-30.96B-43.13B-23.40B---
Capital Expenditure13.89B16.07B10.31B3.78B1.55B2.17B10.17B12.91B4.08B6.83B40.62B10.44B
Free Cash Flow---20.91B12.44B27.81B32.86B45.67B9.40B7.79B-35.01B1.60B
Dividends Paid6.56B4.78B3.53B5.26B1.98B5.82B4.90B8.77B3.94B2.99B2.97B2.88B
FCF to OCF---69.64%56.25%76.83%57.17%68.14%31.40%53.26%-623.49%13.32%
Dividend Paid to FCF---25.15%15.90%20.91%14.92%19.21%41.94%38.42%-8.50%179.64%

Earnings

Report DateJun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Mar 31, 2015Jul 3, 2015Sep 30, 2015Mar 2, 2016Jun 29, 2016Oct 31, 2016Apr 7, 2017Jul 5, 2017Oct 30, 2017Feb 28, 2018Apr 6, 2018Aug 14, 2018Oct 29, 2018Feb 27, 2019Apr 5, 2019Aug 13, 2019Nov 11, 2019Feb 26, 2020Apr 3, 2020Aug 18, 2020Nov 2, 2020Mar 3, 2021May 13, 2021Aug 13, 2021Nov 1, 2021Mar 2, 2022May 17, 2022Aug 16, 2022Nov 14, 2022Mar 1, 2023May 15, 2023Aug 15, 2023Nov 13, 2023May 14, 2024Aug 14, 2024Nov 14, 2024Mar 13, 2025Mar 31, 2025Aug 12, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------------------------
EPS Actual5.886.023.7958.5144.845.9827.9766.8810.6026.146.1838.0412.0730.216.9969.7222.1023.1535.09146.6969.07137.07-121.73183.5081.3060.0188.14122.02-36.50-231.57246.3495.96-110.70-510.68259.5978.56210.42-0.10177.67133.10269.2917.5521.95170.58424.88172.68331.03238.86429.1337.15161.15-161.46268.87112.6160.42192.15191.52190.9931.38459.30-307.39996.58-136.06
Surprise---------------------------------------------------------------
Timing----------------------------------------------------------Pre-market----

Key Statistics & Ratios

Market Cap319.63B
Enterprise Value234.86B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.16
Price / Book0.00
Revenue (TTM)277.96B
Gross Profit (TTM)109.85B
EBITDA-5.26B
Profit Margin6.22%
Operating Margin-10.39%
Return on Equity7.00%
Return on Assets-1.91%
Shares Outstanding18.17M
Shares Float12.75M
Beta0.38
Dividend Yield2.24%
Dividend Rate180.00
Payout Ratio17.78%

Dividends

20251×
180.00Dec 29, 2025
20241×
175.00Dec 27, 2024
20231×
175.00Dec 27, 2023
20221×
175.00Dec 28, 2022
20211×
225.00Dec 29, 2021
20201×
145.00Dec 29, 2020
20191×
145.00Dec 27, 2019
20161×
125.00Dec 28, 2016
20141×
125.00Mar 28, 2014
20131×
125.00Mar 28, 2013
20111×
125.00Mar 30, 2011
20081×
125.00Mar 28, 2008
20071×
150.00Mar 29, 2007
20061×
150.00Mar 30, 2006
20051×
125.00Mar 30, 2005
20041×
100.00Mar 30, 2004
20001×
50.00Mar 30, 2000
19991×
48.54Mar 30, 1999
19981×
48.54Mar 30, 1998
19971×
70.69Mar 29, 1997
19961×
211.78Mar 30, 1996

Stock Splits

  • Jun 28, 20062:1